Barriers to inhaled gene therapy of obstructive lung diseases: A review

Namho Kim, Gregg A. Duncan, Justin Hanes, Jung Soo Suk

Research output: Contribution to journalArticlepeer-review

Abstract

Knowledge of genetic origins of obstructive lung diseases has made inhaled gene therapy an attractive alternative to the current standards of care that are limited to managing disease symptoms. Initial lung gene therapy clinical trials occurred in the early 1990s following the discovery of the genetic defect responsible for cystic fibrosis (CF), a monogenic disorder. However, despite over two decades of intensive effort, gene therapy has yet to help patients with CF or any other obstructive lung disease. The slow progress is due in part to poor understanding of the biological barriers to inhaled gene therapy. Encouragingly, clinical trials have shown that inhaled gene therapy with various viral vectors and non-viral gene vectors is well tolerated by patients, and continued research has provided valuable lessons and resources that may lead to future success of this therapeutic strategy. In this review, we first introduce representative obstructive lung diseases and examine limitations of currently available therapeutic options. We then review key components for successful execution of inhaled gene therapy, including gene delivery systems, primary physiological barriers and strategies to overcome them, and advances in preclinical disease models with which the most promising systems may be identified for human clinical trials.

Original languageEnglish (US)
Pages (from-to)465-488
Number of pages24
JournalJournal of Controlled Release
Volume240
DOIs
StatePublished - Oct 28 2016

Keywords

  • Biological barrier
  • Gene delivery vector
  • Preclinical model
  • Respiratory gene therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Barriers to inhaled gene therapy of obstructive lung diseases: A review'. Together they form a unique fingerprint.

Cite this